Alkem Labs signs licensing agreement with Sonnet BioTherapeutics to develop diabetic neuropathy treatment

October 10, 2024
Uncategorized

Under the licensing agreement, Alkem will carry out the clinical development of ‘SON-080’ in India with support from Sonnet and enable global and India regulatory filings.

Alkem Labs signs licensing agreement with Sonnet BioTherapeutics to develop diabetic neuropathy treatment

Leave a ReplyCancel Reply

NTPC Green Energy Q4 Results: Stock trades below IPO price ahead of earnings

Leela hotels-owner Schloss sets IPO price band for ₹3,500 crore issue

US deficit is a growing threat to global equities: Geoffrey Dennis

TCS winning a ₹2,903 crore order from BSNL leads to a major order win for Tata Group’s Tejas Networks

Rupee falls 9 paise to 85.67 against US dollar in early trade